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Abstract
Background: Osteoarthritis (OA) of the knee is one of the main causes of musculoskeletal disability in the western world.
Current available management options provide symptomatic relief (exercise and self-management, medication and surgery) but
do not, in general, address the disease process itself. Moreover, adverse effects and complications with some of these
interventions (medication and surgery) and the presence of co-morbidities commonly restrict their use. There is clearly a need
to investigate treatments that are more widely applicable for symptom management and which may also directly address the
disease process itself.
In two randomised controlled trials of four and 12 weeks duration, pulsed electrical stimulation was shown to be effective in
managing the symptoms of OA of the knee. Laboratory and animal studies demonstrate the capacity of externally applied electric
and electromagnetic fields to positively affect chondrocyte proliferation and extracellular matrix protein production. This latter
evidence provides strong theoretical support for the use of electrical stimulation to maintain and repair cartilage in the clinical
setting and highlights its potential as a disease-modifying modality.
Methods/Design: A double-blind, randomised, placebo-controlled, repeated measures trial to examine the effectiveness of
pulsed electrical stimulation in providing symptomatic relief for people with OA of the knee over 26 weeks.
Seventy people will be recruited and information regarding age, gender, body mass index and medication use will be recorded.
The population will be stratified for age, gender and baseline pain levels.
Outcome measures will include pain (100 mm VAS and WOMAC 3.1), function (WOMAC 3.1), stiffness (WOMAC 3.1), patient
global assessment (100 mm VAS) and quality of life (SF-36). These outcomes will be measured at baseline, four, 16 and 26 weeks.
Activity levels will be measured at baseline and 16 weeks using accelerometers and the Human Activity Profile questionnaire. A
patient global perceived effect scale (11-point Likert) will be completed at 16 and 26 weeks.
Discussion: This paper describes the protocol for a randomised, double-blind, placebo-controlled trial that will contribute to
the evidence regarding the use of sub-sensory pulsed electrical stimulation in the management of OA of the knee.
Trial registration: Australian Clinical Trials Registry ACTRN12607000492459.
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Osteoarthritis is a major cause of pain and disability in the
community and OA of the knee is one of the most com-
mon causes of musculoskeletal disability in the Western
world [1]. As prevalence increases it is expected to pose an
increased burden on health care in the future.
Management options such as medication, exercise, self-
management programs and surgery largely focus on pro-
viding symptom relief and maintenance of function, but
do not, in general, address the disease process itself. More-
over, adverse effects and complications with some of these
interventions (medication and surgery) and the presence
of co-morbidities commonly restrict their use.
In recent years considerable effort has been directed
towards investigating the effectiveness of putative disease-
modifying OA drugs such as glucosamine, chondroitin
sulfate, doxycycline and diacerein [2-5]. There is also
interest in the use of pulsed electrical stimulation and
electro-magnetic fields as potential OA disease modifying
modalities. Laboratory work and animal studies provide
theoretical support for the use of electrical stimulation to
maintain and repair articular cartilage in the clinical set-
ting [6-10]. However, there are limited studies examining
the effects of pulsed electrical stimulation in humans.
Two randomised, placebo-controlled trials have reported
using capacitively coupled pulsed electrical stimulation
(PES) delivered via skin surface electrodes [11,12]. In
both trials, outcome measures focussing on symptom
relief and functional capacity have been the variables of
interest.
The first of these trials [12] randomised 78 subjects to pla-
cebo or PES treatment with a monophasic, spiked signal
at 100 Hz delivered by the Bionicare® BIO-1000™. PES was
applied for between six and 10 hours per day at an inten-
sity just below the sensory threshold for four weeks.
Response to intervention was better for the active device
than the placebo for the outcome measures of pain, phys-
ical function, physician global assessment and duration of
joint stiffness in the morning (p < 0.05) [12]. No statisti-
cally significant difference was observed for range of knee
joint motion, joint tenderness, joint swelling, knee cir-
cumference and 50 feet walking time.
The second PES trial [11] examined 58 subjects using the
same stimulation device in the same manner over 12
weeks. In this trial significant and clinically meaningful
results were reported in patient global assessment, a pain
and symptom visual analogue scale, WOMAC function
and stiffness and overall WOMAC score. Only WOMAC
pain change between the placebo and active groups did
not reach statistical significance.
No randomised, controlled trials studying this particular
modality over a longer time period have been found.
The modality being investigated is neither invasive nor
pharmaceutical. As the majority of those with OA of the
knee are likely to be elderly, they are also more likely to
have co-morbidities such as heart and lung disease which
increase the anaesthetic risk associated with invasive sur-
gery. Similarly, there is increasing awareness of the
adverse side effects of many of the medications that are
used to manage OA of the knee [13-15]. Consequently, in
a climate where patients are seeking different options in
their disease management strategies, the potential for PES
to provide an effective, safe alternative that is acceptable
to the community is very high.
This research proposes to investigate the longer term effec-
tiveness of PES and to determine the sustainability of
responses in subjects with symptomatic knee OA.
Methods/Design
Study design
A double-blind, randomised, placebo-controlled,
repeated measure trial will be conducted over 26 weeks.
Participants will be assessed, prior to the commencement
of treatment (baseline), and after four, 16 and 26 weeks of
treatment (Figure 1).
Aims and hypothesis
The primary aim is to investigate for a period of 26 weeks,
the effectiveness of transcutaneous PES in the treatment of
symptomatic knee OA. A secondary aim is to determine
whether effects, if any, are influenced by gender, age and/
or baseline pain levels.
The experimental hypothesis is that PES will produce a
clinically important and sustained improvement in pain,
function, patient global assessment, global perceived
effectiveness, quality of life and activity levels when com-
pared with placebo treatment in individuals with sympto-
matic OA of the knee.
Participants
Seventy participants with primary OA of the knee will be
recruited.
Inclusion criteria
• Primary knee OA diagnosed in accordance with the
American College of Rheumatology (ACR) modified clin-
ical classification criteria (sensitivity 84%, specificity
89%) [16,17]. This classification system has been shown
to be a valid tool for OA knee diagnosis [18].Page 2 of 9
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Summary of study procedureFigure 1
Summary of study procedure. ACR – American College of Rheumatology; WOMAC – Western Ontario and McMaster 
Universities Osteoarthritis Index; PGA – Patient Global Assessment; SF-36 – Medical Outcomes Study 36-item Short-Form 
Survey; HAP – Human Activity Profile; GPES – Global Perceived Effectiveness Scale.
 Call for volunteers to study 
Initial assessment of eligibility by telephone screening 
Those fulfilling initial criteria attend visit 1: 
Second and final screening – Completion of ACR modified classification of 
OA knee, assessment of sharp/blunt discrimination and assessment of pain 
VAS. 
Visit 2: (Week 0) 
Instruction on use of medication diary. Instruction on use of PES device. 
Those fulfilling selection criteria continue with visit 1: 
Purpose of the study further explained (both written and verbal form). 
Informed consent obtained and subject allocated identification number. 
Baseline measures of WOMAC pain, stiffness and function, PGA, SF-36 and HAP. 
If current X-ray needed, consent obtained and referral for X-ray written. 
Accelerometer distributed to participant with instructions for use. 
BMI, gender, age, disease laterality and current medication recorded. 
Postal Contact: (Week 4) 
Repeated measures of pain VAS, WOMAC pain, stiffness and function, PGA and SF-36. 
Concealed random allocation stratified for age, gender and pain levels to 
group X (n = 35) or group Y (n = 35) 
Visit 5: (Week 26) 
Return of the PES device and completed medications diary. 
Repeated measures of pain VAS, WOMAC pain, stiffness and function, PGA, GPES and SF-36. 
Exit from study. 
Visit 3: (Week 16) 
Repeat of questionnaires as per week four, plus completion of GPES and HAP. Medication diary 
sighted and record taken of recorded hours of use.  
Accelerometer distributed with instructions for use. 
Visit 4: (Week 17) 
Return of accelerometer 
Blind data analysis, code for placebo and intervention groups revealed and manuscript preparation 
Those excluded 




for not meeting 
selection criteria 
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• Pain score of at least 25 mm on a 100 mm visual ana-
logue scale (VAS).
Exclusion Criteria
• Co-existing inflammatory arthropathies.
• Contraindications to electrical stimulation (pregnancy,
decreased sensory perception, presence of metal in the
field of application, or any implanted electrical stimula-
tion device).
• Skin disorders in the treated knee area.
• Scheduled to have a total knee replacement within six
months of entering the trial.
• Not able to read or understand English.
Procedure
Recruitment
Potential volunteers will be recruited through commu-
nity-based rheumatology and general practices, rheuma-
tology outpatient clinics in teaching hospitals in the Perth
metropolitan area, the Arthritis Foundation of Western
Australia and promotion through media outlets.
Determining eligibility and baseline assessment
Initially volunteers will be telephone-screened to check
for obvious exclusion criteria.
At a screening visit, diagnosis according to the ACR mod-
ified clinical classification will be made, sharp/blunt sen-
sory discrimination will be tested and the pain VAS
completed. Eligible participants who present with bilat-
eral OA of the knee will be asked to nominate which knee
they consider to be the most symptomatic and that knee
will be treated.
Subjects who meet eligibility criteria will receive further
information concerning the trial. In particular, the aims
and methods will be explained in detail following which,
written consent to participate will be sought. This trial has
been approved by the Curtin University Human Research
Ethics Committee (HR122/2006). Following consent,
participants will be assigned an identification number
and will be asked to complete baseline measures of
WOMAC pain, stiffness and function, patient global
assessment, quality of life and the Human Activity Profile
(HAP) test, while details regarding body mass index
(BMI), age, gender, laterality of joint disease, disease
severity (if X-ray available) and current medication will be
recorded. Participants who have not had a plain X-ray
within the past two years will be referred for X-ray. Partic-
ipants who are unwilling to have X-rays taken will not be
excluded from the trial. Available X-rays will be graded
according to the Kellgren and Lawrence radiological grad-
ing system. All outcome measurements will be taken and
all instructions provided by an experienced musculoskel-
etal physiotherapist at Curtin University of Technology. At
this first visit participants will also be provided with an
accelerometer to collect seven days of ambulatory activity,
after which it will be returned in person.
In the interim, participants will be randomly allocated
into groups. Upon returning the accelerometer, they will
be fitted with the PES device and given detailed verbal and
written instructions regarding its use. They will also be
provided a medications diary and relevant instructions.
Randomisation and blinding
An administrator, not otherwise involved with the trial,
will allocate the participants to groups using computer-
generated block randomisation combined with stratifica-
tion. Groups will be stratified with regard to gender, age
(<60, 60–75 and >75), and intensity of pain (VAS scores
25–40, 41–60 and 61–100). The administrator will dis-
pense an appropriate device using a list, provided by the
senior biomedical engineer who modified the devices,
that matches the device serial numbers to active or pla-
cebo. Participant identification will be added to the list at
the time of randomisation so, should the need arise, the
investigators will be able to determine the nature of the
device provided to a participant without risk of becoming
aware of assignment for any other participants (Figure 2).
The measurer though will remain blinded to assignment
throughout.
The group-to-device-to-intervention code will remain in
the possession of the equipment dispensary (protected by
password) until after the data analysis has been com-
pleted.
Trial intervention
A commercially available transcutaneous electrical nerve
stimulator (Metron Digi-10s) has been adapted by a sen-
ior biomedical engineer to produce either a pulsed, expo-
nentially declining waveform with a frequency of 100 Hz
or a placebo device identical in appearance. Participants
will be advised to use the device at a sub-sensory level, to
replicate the conditions in the previous randomised con-
trolled trials, for a minimum of seven hours per day. It
will be recommended that they wear the device overnight.
There is a locking mechanism on the device so that once
the treatment intensity has been set there can be no inad-
vertent intensity change during the course of treatment.
The instructions given to participants by the physiothera-
pist, who remains blind to the nature of the device, will bePage 4 of 9
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are using.
Background therapy
Participants will be asked to continue their normal back-
ground medical management during the trial period. A
medications diary will be used to alert the investigators to
any changes in medication usage. Each subject's manag-
ing doctor will be informed by letter of their patient's par-
ticipation in the trial. Doctors will be requested to refrain
from changing OA management during the period of the
trial if at all possible.
Compliance
Participants will be asked to keep a record of their daily
PES use. This will be maintained within the medications
diary booklet. Intermittent questioning about PES use via
regular phone calls during the trial period and a review of
the booklet at 16 weeks will occur.
Safety monitoring and adverse events
Participants will be encouraged to contact the investiga-
tors should any questions arise during the trial. Corre-
spondingly, they will be asked open-ended questions by
the physiotherapist during the scheduled phoned calls to
determine any adverse effects from using the device. The
Process for stratified randomisation and concealed allocationFigure 2




















• Maintains list with device serial number, group name (X or Y) and 
group identity (active or placebo) 
 
• Randomises participant using identification number to a group name  
 
• Allocates specific device to participant identification number  
 
• Advises clinical investigator which serial numbered device to give to 
participant 
Equipment modification 
• List noting serial number, group 
name (X or Y) and group identity 
(placebo or active) developed when 
equipment modified 
 
• List sent to equipment dispensary 
at Curtin University School of 
Physiotherapy 
Participant enters study 
• Participant identification number, 
along with details of gender, age 
and baseline pain levels, sent by 
clinical investigator to equipment 




• Dispenses device by serial number to participant Page 5 of 9
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tion. This occurred in both the placebo and intervention
groups in both randomised controlled trials in approxi-
mately equal proportions (range 17.9–24% active and 21
– 21.1% placebo) and responded favourably to topical
therapy, a temporary halt in use and/or change in the con-
duction gel [11,12]. Any participant reporting skin irrita-
tion will be asked to stop using the device and to return to
the Curtin University School of Physiotherapy for assess-
ment at the first available opportunity. Should there be
pain, swelling or more than a five centimetre diameter
area of redness after desisting for 48 hours, a medical
opinion will be obtained before proceeding further.
Outcome measures
Outcome measures include the core set of primary efficacy
variables recommended by the Outcome Measures in
Rheumatology Clinical Trials (OMERACT) group for
phase III clinical trials in OA [19] and recommended for
inclusion in OA clinical trials by the Cochrane Collabora-
tion [20].
The three primary efficacy variables, to be measured at base-
line, four, 16 and 26 weeks, are:
• Pain (100 mm VAS and Western Ontario and McMaster
Universities Osteoarthritis Index -WOMAC Likert format
3.1). Two measures for pain will be included as this mir-
rors standard practice in much of the OA literature and it
will provide internal validity for this important outcome
measure. The reliability of the VAS has previously been
demonstrated [21] and is regularly used in this popula-
tion. WOMAC measures health status and assesses pain,
physical function and stiffness in patients with OA of the
hip or knee. The WOMAC questionnaire is self-adminis-
tered and can be completed in less than five minutes. Two
major validity studies have shown that WOMAC pain,
physical function and stiffness subscales are valid and that
the questionnaire is reliable and sensitive enough to
detect changes in health status following a variety of inter-
ventions [22].
• Patient Global Assessment (100 mm VAS as described
by Ehrich et al [23]). Participants are asked to consider all
the ways in which their arthritis is affecting them at the
time of the assessment and indicate by marking the VAS
how they are doing. The left hand anchor of the VAS is
Very Well while the right hand anchor is Very Poorly.
• Physical function (WOMAC Likert format 3.1). Likert
values from 17 questions of the WOMAC are summed to
generate a score for physical function with a higher score
indicating worse function.
Secondary outcome measures
• Quality of life (Medical Outcomes Study 36-item Short-
Form Survey version 2 – SF-36). The SF-36 has eight sub-
component scales reflecting both physical and mental sta-
tus. It is comprised of 36 questions, is self administered,
and can be completed in about 15 minutes. All estimates
of score reliability, from 14 separate studies, for each of
the eight scales of the SF-36 exceeded accepted standards
for measures used in group comparisons [24]. The SF-36
has been extensively validated in many English speaking
countries of the world including Australia [25]. The
rationale for using both WOMAC and the SF-36 for this
trial is that a combined approach using both generic qual-
ity of life and knee specific health status measures is con-
sidered likely to prove best for knee-related problems
[26]. Quality of life measurements will be taken at base-
line, four, 16 and 26 weeks.
• Joint stiffness (WOMAC Likert format 3.1) measured at
baseline, four, 16 and 26 weeks.
• Global perceived effect scale (GPES) measured using an
11-point scale ranging from -5 (vastly worse) to +5 (com-
pletely recovered) with the zero point being unchanged as
reported by Pengal et al [27]. This will be measured at 16
and 26 weeks.
• Physical activity will be determined using the HAP ques-
tionnaire plus accelerometers measured at baseline and
16 weeks.
 The HAP is self-administered. It incorporates 94 activi-
ties listed in ascending order of oxygen cost. Respondents
are asked to indicate whether they are able to perform the
activity unassisted; whether they have ever performed the
activity and whether they have stopped performing the
activity [28]. In a cross-sectional study, the HAP has been
found reliable and sufficiently sensitive for use in people
with OA of the knee [29]. This study demonstrated that
people with OA of the knee are in fact less active than their
healthy counterparts and that there was a relationship
between HAP scores and participants' pain and function
scores. The proposed trial offers the potential to deter-
mine whether improvement in pain and function result in
a spontaneous increase in the level of physical activity.
 Accelerometry is now considered the preferred method
of objectively measuring physical activity as it provides
data that allows individual examination of ambulatory
activity frequency, intensity and duration [30]. However,
to our knowledge accelerometers have not been validated
for use in people with OA of the knee. For this trial an Act-
igraph GT1M (formerly Computer Science and Applica-
tions monitor), the most widely accepted accelerometer in
research, will be utilised [31]. The match-box size acceler-Page 6 of 9
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be asked to wear for a period of seven consecutive days at
both the baseline and 16 week data collection points.
The benefits of physical activity are well known and
include reduced risk of cardiovascular disease, diabetes,
some forms of cancer, osteoporosis, falls and fractures.
Physical activity interventions have also been shown to
assist with weight control and to improve physical func-
tioning and mental health. The impact of physical activity
on OA remains unanswered. Osteoarthritis of the knee is
often associated with considerable knee pain that suggests
that people with knee OA may curtail their physical activ-
ity. Although most studies of OA of the knee measure
changes in function, few measure physical activity levels
so there is limited evidence to demonstrate whether or not
this is the case. Moreover whether treatments that reduce
pain result in an increase in physical activity is yet to be
determined.
Sample Size Calculations
The primary outcome measure will be defined as an
improvement in the absolute pain VAS score of 20. This is
the minimum absolute change necessary for classification
as a responder in the Osteoarthritis Research Society Inter-
national (OARSI) response criteria [32,33]. Assuming no
change in the placebo group, it has been calculated that a
sample size of 70 (35 in each group allowing for 20%
withdrawals) will be sufficient to detect this 20 point
change as well as differences equal to the absolute mini-
mal clinically important improvements of 19.9 (Pain
VAS), 18.3 (PGA) and 9.1 (WOMAC function) described
by Tubach et al [34] with a power of 80% using a two-
tailed test with alpha level of 0.05. Calculations were
based on standard deviations data from Garland et al [11]
(Pain VAS and PGA) and Raynauld et al [35] (WOMAC
function).
Statistical Analysis
All analyses will be performed on an intention to treat
basis while the investigators remain blind to treatment
groups. Change in pain between baseline and 26 weeks
will be compared between groups using the independent
t-test. To test for the fixed effect of treatment while adjust-
ing for any differences in the baseline measures, repeated
measures analysis using a linear mixed model will also be
performed for pain VAS, patient global assessment,
WOMAC function, stiffness and pain, and QOL measure-
ments taken at four, 16 and 26 weeks. There will be no
adjustment for multiple comparisons as all comparisons
have been determined a priori and, while adjustment
maintains study wise error, it may preclude detection of
clinically important differences [36].
Change in activity level between baseline and 16 weeks
will also be analysed using the independent t-test. Second-
ary analyses such as the proportion of participants achiev-
ing minimal clinically important improvements in pain,
function and patient global assessment at each observa-
tion time will be compared using the Chi-square test.
GPES at 16 weeks and 26 weeks will be compared between
groups using unpaired t-tests.
Ethical considerations
A placebo control is being used in this trial. However, as
subjects are not being asked to change their usual treat-
ment regimen, no subject will be disadvantaged by using
the placebo.
Data Quality
Data will be entered into a specifically designed database
with pop-up value lists, value ranges, data type and field
complete validations. Random scrutiny by co-investiga-
tors of at least ten percent of all data entered will be con-
ducted throughout the trial to ensure accuracy and
completeness.
Timelines for E-PES trial
Patient recruitment and initial phone screening began in
July 2007. Final screening and data collection com-
menced in October 2007 with final exit data expected to
be collected in February 2009.
Discussion
This paper describes the rationale and protocol for con-
ducting a double-blind, randomised, placebo-controlled
trial that will investigate the use of pulsed electrical stim-
ulation in the management of OA of the knee. It incorpo-
rates features designed to minimise bias [37] and uses
valid outcome measures that will facilitate comparability
with other research in the area.
This trial will contribute to the evidence regarding the use
of a non-pharmaceutical, non-invasive modality in man-
aging symptoms of OA of the knee. Given the modality's
simple technology and ease of use (patients can readily
use it at home), it has huge potential to provide a safe,
effective treatment option for clinicians.
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